Background and Objectives: There are still needs for new therapy for treatment of Type 2 Diabetes Mellitus (T2DM). Bromocriptine has several advantages including plasma glucose and lipid reduction. This study was designed to examine the effectiveness of Bromocriptine on glycemic control in poorly controlled T2DM patients. Material and Methods: In the present clinical trial study, 43 T2DM patients were investigated. Bromocriptine was administrated with a dose of 1.25 mg/day orally at bedtime. The mentioned dose was gradually increased up to 2.5 mg twice aday. The demographic characteristics, height, weight, fasting blood glucose, 2-hour postprandial blood sugar, glycosylated hemoglobin (HbA1C), lipid profile and creatinine were measured. Patients were followed-up during 1.5, 3, and 6 months later. Results: The mean age of study was 55.0±7.2 years. Mean of baseline fasting blood glucose of patients were decreased from 184.3 mg/dL to 155.5, 148.9 and 159.5 mg/dL in 1.5, 3 and 6 months after treatment, respectively (p<0.0001). Two-hour postprandial blood sugarreached to 217.0, 205.1 and 201.0 mg/dL in baseline times from 276.6 mg/dL (p<0.0001). After three months observation, there was 0.8% reduction in HbA1C whereas, it was 0.9% in month six (p<0.0001). Conclusion: The concomitant treatment with bromocriptine and other antiglycemic drugs was effective in glycemic control of T2DM cases.